C2541013 MIRNA NASH  

is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver

TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.  

The AURORA Study

Assessing the efficacy and safety of Cenicriviroc for the treatment of liver fibrosis in adults with non-alcoholic steatohepatitis (NASH)  

NASH (Nonalcoholic Steatohepatitis)

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver.  ClinSearch is enrolling volunteers with a condition called liver fibrosis from NASH

C3711005  

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS

The study aims to evaluate The effect of oral (PO) CC-90001, administered once daily (QD), compared with placebo, will be evaluated in subjects with NASH and Stage 3 fibrosis and explored in subjects with NASH and Stage 4 fibrosis. This study is designed to assess response to treatment on measures …

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)